This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pfizer (PFE) Q4 Earnings Lag, Sales Top; '17 Sales View Soft
by Kinjel Shah
Pfizer, Inc. (PFE) missed earnings estimates in the fourth quarter.
Dow 30 Stock Roundup: Boeing, Caterpillar, Johnson & Johnson, DuPont Beat on Earnings
by Swarup Gupta
The Dow gained over the week following continuing optimism over Trump's first actions as President and encouraging earnings results.
Merck (MRK): Stock to Gain on Likely Earnings Beat in Q4?
by Zacks Equity Research
We expect pharma heavyweight Merck & Co., Inc. (MRK) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Feb 2.
J&J to Acquire Actelion for $30B: Is It a Strategic Fit?
by Zacks Equity Research
Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Actelion (ALIOF) for $280 per share, as of Jan 25, 2017, in an all-cash transaction.
For $30 Billion, Johnson & Johnson is Acquiring Swiss Biotech Actelion
by Madeleine Johnson
On Thursday, healthcare giant Johnson & Johnson (JNJ) announced it will acquire Swiss biotechnology company Actelion for $30 billion in order to boost its roster of rare disease treatments.
Biogen (BIIB) Q4 Earnings Top Estimates; '17 Sales View Soft
by Zacks Equity Research
Biogen Inc. (BIIB), a well-known name in the multiple sclerosis (MS) market, reported mixed fourth-quarter 2016.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Biogen, Celgene and Bristol-Myers Squibb
What Lies in Store for Pfizer (PFE) this Earnings Season?
by Zacks Equity Research
Pfizer Inc. (PFE) will be reporting fourth-quarter and full-year 2016 earnings results on Jan 31, before market open.
Drug Stock Earnings to Watch on Jan 26: BIIB, CELG & BMY
by Zacks Equity Research
How will these three drug stocks, CELG, BMY and BIIB, which are all scheduled to report Q4 results on Jan 26, fare this earnings season?
Is Customer Satisfaction the Hidden Key to Stock Outperformance?
by Eric Dutram
In this edition of the Dutram Report, we take a closer look at the idea of customer satisfaction. Do companies that serve their customers better end up being more impressive investments? In order to get to the bottom of this, I spoke with Kevin Quigg, Chief Strategist of ACSI Funds for some answers and insights.
Sunesis Offers Updates on SNS-062 and Qinprezo Programs
by Zacks Equity Research
Sunesis (SNSS) provided updates on two of its lead programs: SNS-062, and Qinprezo (vosaroxin).
Can AbbVie (ABBV) Spring a Surprise This Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.
Q4 Earnings Roundup: JNJ, VZ, MMM, DD, Etc.
by Mark Vickery
Ahead of the opening bell today, we have plenty of Q4 earnings results to report.
J&J (JNJ) Q4 Earnings Top; Seeks Options for Diabetes Unit
by Zacks Equity Research
Johnson & Johnson (JNJ) reported a mixed quarter with earnings beating expectations while sales missing the same.
The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman Sachs, DuPont, Johnson & Johnson, Verizon Communications and Travelers Companies
J&J (JNJ) Beats on Q4 Earnings, Sales Miss; Stock Down
by Zacks Equity Research
JNJ beat on fourth quarter earnings - the company reported EPS of $1.58 while our consensus called for EPS of $1.56.
The Best Earnings Charts on the Street
by Tracey Ryniec
It's not easy to beat on earnings every quarter for years but these companies are doing it.
Dow Stocks to Watch for Earnings on Nov 24: DD, JNJ, TRV, VZ
by Swarup Gupta
The nature of these releases is likely to determine the fortunes of the Dow in the days ahead.
Can Q4 Earnings Revitalize Healthcare ETFs?
by Sweta Killa
The Q4 earnings could bring some near-term relief given that the sector is expected to post earnings growth of 2.9% and revenue growth of 5.6%.
5 Best Performing Healthcare Mutual Funds of 2016
by Zacks Equity Research
Investors rely on the healthcare firms to safeguard their investments as demand for its services does not vary much with market conditions
J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio
by Zacks Equity Research
Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.
What's in Store for Abbott Labs (ABT) This Earnings Season?
by Zacks Equity Research
Abbott Laboratories (ABT) is scheduled to report fourth-quarter and full year 2016 results before the opening bell on Jan 25.
Abbvie (ABBV) Imbruvica Approved in Lymphoma Indication
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that the FDA has approved its blood cancer drug, Imbruvica, for the treatment of patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
What???s Ahead for Johnson & Johnson (JNJ) in Q4 Earnings?
by Zacks Equity Research
Johnson & Johnson (JNJ), the bellwether of healthcare companies, is scheduled to report fourth-quarter 2016 and full-year results on Jan 24.
Stock Market Roundup Jan. 11: Health Sector Lower on Trump "Murder" Comment
by Madeleine Johnson
After President-elect Donald Trump said pharmaceutical companies were ???getting away with murder,??? in how much they charge the government for medicines.